January 09, 2025 12:31 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
6 dead in stampede near Tirupati temple during token distribution to offer prayers | Prominent journalist-film producer Pritish Nandy dies of cardiac arrest at 73 | Thousands, including Hollywood stars, flee Los Angeles upscale neighbourhood as wildfire engulfs homes | Sheesh Mahal row: AAP leaders who were denied entry into CM's residence turn towards PM's house | Anna University sexual assault accused is a DMK supporter, not member: MK Stalin | Ajit Doval, Raja Dato discuss bilateral cooperation during India-Malaysia Security Dialogue | US President-elect Donald Trump threatens to use economic force to make Canada 51st US State, Justin Trudeau retorts sharply | Elon Musk raises concern on 'world population decline' including that of India, China | Indian-origin Anita Ananda might replace Justin Trudeau as Canadian PM | 'I won't bite': Kamala Harris tells Senator's husband as he refuses to shake hands with her
Glenmark Life Sciences Limited initial public offer to open on July 27

Glenmark Life Sciences Limited initial public offer to open on July 27

Jul 21, 2021, at 11:04 pm

Kolkata: Glenmark Life Sciences Limited, a manufacturer of active pharmaceutical ingredients, plans to open its Initial Public Offering (“Offer”) on July 27, 2021.

Glenmark Pharma receives ANDA approval for Fingolimod Capsules, 0.5 mg

Glenmark Pharma receives ANDA approval for Fingolimod Capsules, 0.5 mg

Jun 19, 2020, at 04:44 pm

Mumbai/UNI:  Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

May 12, 2020, at 07:55 pm

MUMBAI/PRNewswire -- Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India. Favipiravir is a generic version of Avigan® of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020.